Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

Heinz Ludwig; Meletios A. Dimopoulos; Philippe Moreau; Wee Joo Chng; Hartmut Goldschmidt; Roman Hájek; Thierry Facon; Ludek Pour; Ruben Niesvizky; Albert Oriol; Laura Rosiñol; Aleksandr Suvorov; Gianluca Gaidano; Tomas Pika; Katja Weisel; Vesselina Goranova-Marinova; Antonio Palumbo; Heidi H. Gillenwater; Nehal Mohamed; Sanjay Aggarwal; Shibao Feng; Douglas Joshua

doi:10.1080/10428194.2017.1298755

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

Heinz Ludwig
, Meletios A. Dimopoulos
, Philippe Moreau
, Wee Joo Chng
, Hartmut Goldschmidt
, Roman Hájek
, Thierry Facon
, Ludek Pour
, Ruben Niesvizky
, Albert Oriol
, Laura Rosiñol
, Aleksandr Suvorov
, Gianluca Gaidano
, Tomas Pika
, Katja Weisel
, Vesselina Goranova-Marinova
, Antonio Palumbo
, Heidi H. Gillenwater
, Nehal Mohamed
, Sanjay Aggarwal

Shibao Feng, Douglas Joshua

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Lettera › peer review

Lingua originale	Inglese
pagine (da-a)	2501-2504
Numero di pagine	4
Rivista	Leukemia and Lymphoma
Volume	58
Numero di pubblicazione	10
DOI	https://doi.org/10.1080/10428194.2017.1298755
Stato di pubblicazione	Pubblicato - 3 ott 2017

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Accesso al documento

10.1080/10428194.2017.1298755

Altri file e collegamenti

Link to publication in Scopus

Cita questo

Ludwig, H., Dimopoulos, M. A., Moreau, P., Chng, W. J., Goldschmidt, H., Hájek, R., Facon, T., Pour, L., Niesvizky, R., Oriol, A., Rosiñol, L., Suvorov, A., Gaidano, G., Pika, T., Weisel, K., Goranova-Marinova, V., Palumbo, A., Gillenwater, H. H., Mohamed, N., ... Joshua, D. (2017). Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leukemia and Lymphoma, 58(10), 2501-2504. https://doi.org/10.1080/10428194.2017.1298755

@article{1deb7336bfb84c87ab88bb1a9cfc10c1,

title = "Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup",

author = "Heinz Ludwig and Dimopoulos, \{Meletios A.\} and Philippe Moreau and Chng, \{Wee Joo\} and Hartmut Goldschmidt and Roman H{\'a}jek and Thierry Facon and Ludek Pour and Ruben Niesvizky and Albert Oriol and Laura Rosi{\~n}ol and Aleksandr Suvorov and Gianluca Gaidano and Tomas Pika and Katja Weisel and Vesselina Goranova-Marinova and Antonio Palumbo and Gillenwater, \{Heidi H.\} and Nehal Mohamed and Sanjay Aggarwal and Shibao Feng and Douglas Joshua",

note = "Funding Information: The ENDEAVOR study was supported by Onyx Pharmaceuticals, Inc., an Amgen subsidiary. The authors would like to thank Jesse Potash of Amgen Inc. for medical writing assistance.",

year = "2017",

month = oct,

day = "3",

doi = "10.1080/10428194.2017.1298755",

language = "English",

volume = "58",

pages = "2501--2504",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor and Francis Ltd.",

number = "10",

}

Ludwig, H, Dimopoulos, MA, Moreau, P, Chng, WJ, Goldschmidt, H, Hájek, R, Facon, T, Pour, L, Niesvizky, R, Oriol, A, Rosiñol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Palumbo, A, Gillenwater, HH, Mohamed, N, Aggarwal, S, Feng, S & Joshua, D 2017, 'Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup', Leukemia and Lymphoma, vol. 58, n. 10, pagg. 2501-2504. https://doi.org/10.1080/10428194.2017.1298755

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. / Ludwig, Heinz; Dimopoulos, Meletios A.; Moreau, Philippe et al.
In: Leukemia and Lymphoma, Vol. 58, N. 10, 03.10.2017, pag. 2501-2504.

Risultato della ricerca: Contributo su rivista › Lettera › peer review

TY - JOUR

T1 - Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma

T2 - results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

AU - Ludwig, Heinz

AU - Dimopoulos, Meletios A.

AU - Moreau, Philippe

AU - Chng, Wee Joo

AU - Goldschmidt, Hartmut

AU - Hájek, Roman

AU - Facon, Thierry

AU - Pour, Ludek

AU - Niesvizky, Ruben

AU - Oriol, Albert

AU - Rosiñol, Laura

AU - Suvorov, Aleksandr

AU - Gaidano, Gianluca

AU - Pika, Tomas

AU - Weisel, Katja

AU - Goranova-Marinova, Vesselina

AU - Palumbo, Antonio

AU - Gillenwater, Heidi H.

AU - Mohamed, Nehal

AU - Aggarwal, Sanjay

AU - Feng, Shibao

AU - Joshua, Douglas

N1 - Funding Information: The ENDEAVOR study was supported by Onyx Pharmaceuticals, Inc., an Amgen subsidiary. The authors would like to thank Jesse Potash of Amgen Inc. for medical writing assistance.

PY - 2017/10/3

Y1 - 2017/10/3

UR - https://www.scopus.com/pages/publications/85015635745

U2 - 10.1080/10428194.2017.1298755

DO - 10.1080/10428194.2017.1298755

M3 - Letter

SN - 1042-8194

VL - 58

SP - 2501

EP - 2504

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 10

ER -